Can gadolinium be given safely to a patient on dialysis?

Seminars in Dialysis

Volumn 24, Issue 4, 2011, Pages 370-371

  Rodby, Roger A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

CHEMICALLY INDUCED DISORDER; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; RENAL REPLACEMENT THERAPY;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; RENAL DIALYSIS;

EID: 80051806973     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00895.x     Document Type: Note

References (9)

1. Gadolinium MRI/MRA Causes Nephrogenic Systemic Fibrosis (a skin and tissue condition) in Kidney Disease patients: Website for law firm of Levin, Simes, Kaiser & Gornick: Available at, accessed January 18, 2011
2. Grobner T: Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104-1108, 2006
3. Kanal E, et al.: ACR guidance document safe MR practices: 2007. Am J Roentgenol 188:1-27, 2007
4. Perazella MA, et al.: Nephrogenic systemic fibrosis: a devastating complication of gadolinium in patients with renal impairment. Vasc Dis Manag 4:45-47, 2007
5. Perazella MA, et al.: Gadolinium use in patients with kidney disease: a cause for concern? Semin Dial 20(3):1-4, 2007
6. Perazella MA, et al.: Gadolinium induced nephrogenic systemic fibrosis in patients with kidney disease. Am J Med 120:561-562, 2007
7. FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. Available at, accessed January 18, 2011
8. Broome DR, et al.: Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188(2):586-592, 2007
9. Rodby RA: Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients. Semin Dial 21(2):145-149, 2008